Northern Trust’s Melinta Therapeutics, Inc. Common Stock MLNT Stock Holding History

Northern Trust’s Portfolio MLNT Stock Details MLNT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q1	–	Sell	-17,495	Closed	-$9K	–	4333
2019 Q4	$9K	Sell	17,495 -355	-2%	-$861	﹤0.01%	4205
2019 Q3	$68K	Sell	17,850 -54,605	-75%	-$197K	﹤0.01%	4006
2019 Q2	$482K	Sell	72,455 -5,984	-8%	-$22.8K	﹤0.01%	3559
2019 Q1	$278K	Sell	78,439 -319	-0.4%	-$1.73K	﹤0.01%	3696
2018 Q4	$312K	Buy	78,758 +923	+1%	+$11.8K	﹤0.01%	3663
2018 Q3	$1.54M	Buy	77,835 +27,118	+53%	+$686K	﹤0.01%	3339
2018 Q2	$1.61M	Buy	50,717 +17,495	+53%	+$630K	﹤0.01%	3311
2018 Q1	$1.23M	Buy	33,222 +10,777	+48%	+$709K	﹤0.01%	3314
2017 Q4	$1.77M	Buy	+22,445	New	+$1.66M	﹤0.01%	3205

Northern Trust's MLNT Position: Q1 2020 in Review

Northern Trust sold out of Melinta Therapeutics, Inc. Common Stock (MLNT) in Q1 2020, closing a stake of 17,495 shares — an estimated $9K sold.

Northern Trust first reported a position in MLNT in Q4 2017 and held it in 9 quarters. The position peaked at $1.77M in Q4 2017. 2 funds tracked by Wall St. Rank hold MLNT as of Q1 2020.

Northern Trust reported no remaining Melinta Therapeutics, Inc. Common Stock position as of Q1 2020 after selling out during the quarter.
Northern Trust sold 17,495 Melinta Therapeutics, Inc. Common Stock shares in Q1 2020, an estimated $9K.
Northern Trust first reported a position in Melinta Therapeutics, Inc. Common Stock in Q4 2017 and held it in 9 quarters.
Northern Trust's Melinta Therapeutics, Inc. Common Stock position peaked at $1.77M in Q4 2017.
2 funds tracked by Wall St. Rank held Melinta Therapeutics, Inc. Common Stock as of Q1 2020.

Based on Northern Trust's 13F filing for Q1 2020, filed 14 May 2020.